BackTheravance Biopharma Overview
Theravance Biopharma Inc

Theravance Biopharma Target Price

Analysts' average 12-month price target for Theravance Biopharma is $17.

Get informed when a big investor buys or sells

+ Follow

Share Price

$16.92

Average Target Price

$17.000.5% upside

1 analysts in the last 4 months

High: $17 | Low: $17

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-07H.C. Wainwright$170.5% upsideOpen
2026-03-04B.Riley FinancialMayank Mamtani$1417.3% downsideOpen
2025-12-03Oppenheimer$2759.6% upsideOpen
2025-11-26BTIG$40136.4% upsideOpen
2024-11-13Leerink PartnersDavid Risinger$1040.9% downsideOpen
2024-08-06H.C. WainwrightDouglas Tsao$1511.3% downsideOpen
2024-04-12BTIGJulian Harrison$2124.1% upsideOpen
2022-11-17Leerink Partners$1417.3% downsideOpen

Theravance Biopharma (TBPH) FAQ

As of the most recent data, TBPH shows a target price of $17. Scroll down for historical charts and peer comparison views.

If Theravance Biopharma moved to the average analyst target of $17, shares would be roughly 0.5% higher than $16.92. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Theravance Biopharma's earnings trajectory.

Besides this target price page, Stockcircle has Theravance Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $17) with ownership activity and broader fundamentals.

Theravance Biopharma's target price is $17; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.